| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 1x2h,1x90min,1x30min |
| Standardrange | 25-1000pg/mL |
| Specimen/Volumes | 25µLCSF |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | EU:CE |
IBLcomplementsits
dementiaMarkerrange
Furtherimprovementinthediagnosisofneurodegenerativediseases
Alongwithamyloid-βplaques,theformationoftaufibrilswithinthenervecells,particularlyinthecerebralcortexandnotablyinthelimbiclobe,isanotherpathologicalhallmarkofAlzheimer"sdisease.TheconcentrationofTauintheCSFisamarkerofneuronalcelldeath.InAlzheimer"sdisease,however,itincreasesonlyatalaterstageofthediseasewhenthepatientalreadydisplayssignificantcognitiveimpairment.Therefore,thedeterminationoftotaltauinCSFisimportantforthediagnosisofAlzheimer"sdiseaseinadditiontothedeterminationofamyloidβ-peptides.However,increasedtaulevelsarefoundinotherneurodegenerativediseasesaswell.Thesedisordersaregenerallyreferredtoastauopathiesandinclude,interalia,frontotemporallobardegeneration(FTLD),Pick"sdiseaseandcorticobasaldegeneration(CBD).TaulevelsaremarkedlyelevatedinCreutzfeldt-Jakobdisease.
ThehTAUtotalELISAfromAnalytikJena,manfuacturedbyAJRoboscreenanddistributedbyIBLInternational,wasoptimizedsothatitcanbeprocessedinparallelwiththeIBLAmyloid-βCSFELISA.
Asthegraphbelowshows,thehTAUtotalELISAfromAnalytikJena,manufacturedbyAJRoboscreenanddistributedbyIBLInternational,correlatessuperblywiththeINNOTEST®hTAU.
ClinicalvalidationoftheTAUtotalELISAwasperformedattheUniversityHospitalErlangenintheCSFLaboftheDepartmentofPsychiatryandPsychotherapy(Prof.Dr.Lewczuk).TaulevelsinthecerebrospinalfluidofpatientswithAlzheimer"sdiseaseandmildcognitiveimpairment(collectivelyAD(n=72)andcontrolsubjects(n=41))showhighlysignificantdifferencesbetweenthegroups.
Naturally,theTAUtotalELISA,justlikeourAmyloid-βCSFELISAs,displaysanexcellentanalyticalprecisionwithaninter-assayvarianceof<5% (Table 1), intra-assay variance of <5% (Table 2) and inter- LOT and operator variance of <6% (Table 3).
TAUtotalELISA Sample MW CV [pg/mL] [%] 1 182 4.7 2 315 4.4 3 343 4.3
TAUtotalELISA Sample MW CV [pg/mL] [%] 1 179 4.5 2 307 2.7 3 338 2.1
TAUtotalELISA Sample MW CV [pg/mL] [%] 1 180 5.7 2 311 4.4 3 342 5.6
AdditionaladvantagesofourELISAare:
- Dayassay(4hours)
- SameprotocolasAmyloid-βCSFELISAs
- Kitcontrols
- Itlendsitselftoautomation
GeneralInformation
In2010,thenumberofdementiapatientsworldwidewasestimatedat36million.Assuminganongoinglackofsufficientpreventiveandcurativetreatments,thisisexpectedtodoubleevery20years.Alzheimer’sDiseaseaccountsforroughly60‐70%ofalldementiacases.Bothprevalenceandincidenceincreasewithage.Prevalenceisaround1%
inthoseaged65‐69,andmorethan30%inthoseaged90orolder.
ThefirstcaseofAlzheimer’sDiseasewasdefinedandreportedin1907byGermanscientistDr.AloisAlzheimer.HedescribedtwohallmarksoftheDisease‐theplaquesandtanglesinthebrainsofAlzheimer’spatients.TheplaquesareformedbyAmyloid-betapeptidedepositsandthetanglesarecomposedofhyperphosphorylatedTauproteins.
Amyloidosisoccursasearlyasthepreclinicalstage.Thefirstcognitivedeficitscanmanifestthemselvesinthemildcognitiveimpairment(MCI)stage,whileinthedementiastagepatientsareunabletodoanyworkordailychores.
TheconcentrationofTAUinCSFisthereforerecognizedasaonebiomarkerindiagnosingAlzheimer’sDisease.
Moreover,anumberofindependentstudiesshowedthatcombiningTAU‐proteinandamyloid‐beta(1‐42)levelswillenhancespecificityandsensitivityofdiagnosisofAlzheimer’sDisease,whichisfurtherenhancedwhencombiningTAUlevelstoAmyloid-betaratiomeasurement.
本网站将在规定时间内给予删除等相关处理。
